These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36470502)

  • 21. Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection.
    Desai AN; Thompson GR; Neumeister SM; Arutyunova AM; Trigg K; Cohen SH
    JAMA; 2022 Oct; 328(13):1348-1350. PubMed ID: 35994281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital.
    Mondi A; Gagliardini R; Mazzotta V; Vita S; Carletti F; Pinnetti C; Giancola ML; Specchiarello E; Lanini S; Faraglia F; Minosse C; Paulicelli J; Mariano A; Rozera G; Fontana C; Faccendini P; Maggi F; Girardi E; Vaia F; Nicastri E; Antinori A
    J Infect; 2023 Jan; 86(1):66-117. PubMed ID: 36347428
    [No Abstract]   [Full Text] [Related]  

  • 23. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
    Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
    Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 2022 human monkeypox outbreak: Clinical review and management guidance.
    Aldhaeefi M; Rungkitwattanakul D; Unonu J; Franklin CJ; Lyons J; Hager K; Daftary MN
    Am J Health Syst Pharm; 2023 Jan; 80(2):44-52. PubMed ID: 36259674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult.
    Dammann F; Raja M; Camargo JF
    Transpl Infect Dis; 2023 Feb; 25(1):e14022. PubMed ID: 36714983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review.
    Ivanov DT; Slabakova YA; Argirova RM; Valkov TK
    Infez Med; 2023; 31(2):186-194. PubMed ID: 37283638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monkeypox Virus (MPXV) Infection: A Review.
    Kumari R; Arya P; Yadav SP; Mishra RC; Yadav JP
    Infect Disord Drug Targets; 2024; 24(4):76-82. PubMed ID: 38243966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monkeypox treatment: Current evidence and future perspectives.
    Khani E; Afsharirad B; Entezari-Maleki T
    J Med Virol; 2023 Jan; 95(1):e28229. PubMed ID: 36253931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
    De Clercq E; Jiang Y; Li G
    Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.
    Gigante CM; Takakuwa J; McGrath D; Kling C; Smith TG; Peng M; Wilkins K; Garrigues JM; Holly T; Barbian H; Kittner A; Haydel D; Ortega E; Richardson G; Hand J; Hacker JK; Espinosa A; Haw M; Kath C; Bielby M; Short K; Johnson K; De La Cruz N; Davidson W; Hughes C; Green NM; Baird N; Rao AK; Hutson CL
    MMWR Morb Mortal Wkly Rep; 2024 Oct; 73(40):903-905. PubMed ID: 39388389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate.
    Warner BM; Klassen L; Sloan A; Deschambault Y; Soule G; Banadyga L; Cao J; Strong JE; Kobasa D; Safronetz D
    Sci Transl Med; 2022 Nov; 14(673):eade7646. PubMed ID: 36318038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment efficacy of cidofovir and brincidofovir against clade II Monkeypox virus isolates.
    Prévost J; Sloan A; Deschambault Y; Tailor N; Tierney K; Azaransky K; Kammanadiminti S; Barker D; Kodihalli S; Safronetz D
    Antiviral Res; 2024 Nov; 231():105995. PubMed ID: 39243894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of
    Chiem K; Nogales A; Lorenzo M; Morales Vasquez D; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Martínez-Sobrido L
    Microbiol Spectr; 2023 Aug; 11(4):e0474522. PubMed ID: 37278625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome.
    Viguier C; de Kermel T; Boumaza X; Benmedjahed NS; Izopet J; Pasquier C; Delobel P; Mansuy JM; Martin-Blondel G
    Int J Infect Dis; 2022 Dec; 125():135-137. PubMed ID: 36397606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The outbreak of the monkeypox virus in the shadow of the pandemic.
    Majie A; Saha R; Sarkar B
    Environ Sci Pollut Res Int; 2023 Apr; 30(17):48686-48702. PubMed ID: 36854947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
    Bourner J; Redji Mbrenga FD; Malaka CN; Dunning J; Rojek A; Fandema E; Horby P; Boum Y; Nakouné E; Olliaro P
    PLoS One; 2024; 19(5):e0278957. PubMed ID: 38722986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic strategies to address monkeypox.
    McCarthy MW
    Expert Rev Anti Infect Ther; 2022 Oct; 20(10):1249-1252. PubMed ID: 35953443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
    O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying potential monkeypox virus inhibitors: an
    Ashley CN; Broni E; Wood CM; Okuneye T; Ojukwu MT; Dong Q; Gallagher C; Miller WA
    Front Cell Infect Microbiol; 2024; 14():1351737. PubMed ID: 38500508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat.
    Hernandez LE; Jadoo A; Kirsner RS
    Lancet; 2022 Sep; 400(10355):e8. PubMed ID: 36088950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.